Deutsche Bank analyst Pito Chickering raised the firm’s price target on Encompass Health to $70 from $62 and keeps a Buy rating on the shares. The company’s earnings call played out as the firm expected, with Encompass reporting "impressive" Q4 results and solid, yet conservative, 2023 guidance, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EHC:
- Encompass Health price target raised to $75 from $70 at Truist
- Encompass Health price target raised to $69 from $65 at Mizuho
- Encompass Health price target raised to $73 from $62 at Credit Suisse
- Encompass Health price target raised to $73 from $68 at UBS
- Encompass Health sees FY23 adjusted EPS $2.87-$3.16, consensus $3.25